Allergan completes takeover of Tobira Therapeutics

Allergan has announced the completion of its takeover of Tobira Therapeutics in a deal worth $1.695 billion (1.37 billion pounds).

The clinical-stage biopharmaceutical company is focused on developing and commercialising therapies for nonalcoholic steatohepatitis and other liver diseases, meaning the takeover will position Allergan for further growth in these areas.

Following the takeover, the drugs cenicriviroc and evogliptin – which are designed to treat of the multi-factorial elements of NASH, including inflammation, metabolic syndromes and fibrosis – will be added to Allergan's global gastroenterology research and development pipeline.

NASH is a severe type of non-alcoholic fatty liver disease characterised by the accumulation of fat in the liver with no other apparent causes. It can lead to fibrosis of the liver and eventually progress to cirrhosis, portal hypertension, liver cancer and eventual liver failure.

David Nicholson, chief research and development officer of Allergan, said: "The completion of the acquisition of Tobira positions Allergan well in developing novel treatments for NASH, a disease set to become one of the next epidemic-level chronic diseases society faces."

This follows the company's recent announcement that it will also soon be acquiring the gastrointestinal disease specialist Motus Therapeutics.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.